We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid Stool Test Could Help Pinpoint IBD Diagnosis

By LabMedica International staff writers
Posted on 19 Jan 2026

Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. More...

Diagnosis and disease monitoring often depend on colonoscopy, an invasive and costly procedure that many patients undergo repeatedly. Existing stool tests measure general inflammation markers and cannot reliably pinpoint whether inflammation originates in the gut. Researchers have now developed a tool that directly detects gut-specific immune activity in fecal samples, offering a more precise and less invasive approach.

In the research led by the University of Edinburgh (Scotland, UK), investigators focused on granzyme A (GzmA), an enzyme released by overactive T cells that are known to drive tissue damage and inflammation in IBD. After identifying elevated GzmA levels in inflamed intestinal tissue from IBD patients, the team designed an optical luminescent reporter that emits light when it detects GzmA activity.

The reporter produces stronger light signals when enzyme activity is higher, allowing inflammation levels to be quantified directly from stool samples. Unlike conventional fecal tests that measure indirect markers such as calprotectin, this approach targets a molecule closely linked to immune-driven gut inflammation. The tool is designed to be fast, sensitive, and compatible with non-invasive stool testing workflows.

The luminescent reporter was tested on 150 stool samples from both IBD patients and healthy individuals. When combined with standard fecal calprotectin testing, the new method identified IBD more accurately than calprotectin alone. The findings, published in the journal Gut, demonstrate that measuring GzmA activity provides additional, disease-relevant information.

Researchers suggest that the ability to detect gut-specific immune activity could reduce unnecessary colonoscopies and enhance diagnostic confidence. The tool could also support personalized treatment by enabling rapid monitoring of inflammation levels in response to therapy. Further validation studies are planned before the approach can be translated into routine clinical use.

“The speed and sensitivity of our optical tool has the potential to accelerate future studies into the roles of the immune system in IBD, as well as improving the pathway to diagnosis,” said Professor Marc Vendrell, study lead. “In the future, these optical tools could also be used to help tailor treatments for IBD patients.”

Related Links:
University of Edinburgh


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.